Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Price Target at $35.71

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has earned an average rating of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $35.71.

Several analysts have commented on DAWN shares. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, August 1st. Needham & Company LLC reissued a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, July 30th. Piper Sandler restated an “overweight” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. JPMorgan Chase & Co. dropped their target price on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Finally, Bank of America upgraded shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their price target for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st.

Day One Biopharmaceuticals Stock Up 0.2 %

Shares of DAWN opened at $13.79 on Friday. The company has a 50 day moving average of $14.28 and a two-hundred day moving average of $14.56. Day One Biopharmaceuticals has a twelve month low of $9.67 and a twelve month high of $18.07. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -5.49 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.70. The firm had revenue of $8.19 million during the quarter, compared to analyst estimates of $0.90 million. On average, sell-side analysts expect that Day One Biopharmaceuticals will post -1.68 EPS for the current year.

Insider Activity

In related news, Director Saira Ramasastry sold 10,000 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $13.19, for a total transaction of $131,900.00. Following the transaction, the director now directly owns 40,485 shares in the company, valued at $533,997.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the sale, the insider now directly owns 1,097,535 shares of the company’s stock, valued at approximately $15,606,947.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Saira Ramasastry sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction on Friday, June 21st. The stock was sold at an average price of $13.19, for a total value of $131,900.00. Following the transaction, the director now owns 40,485 shares in the company, valued at approximately $533,997.15. The disclosure for this sale can be found here. Insiders sold 78,748 shares of company stock worth $1,141,172 over the last three months. Insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC purchased a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at approximately $29,000. Quintet Private Bank Europe S.A. grew its position in Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares during the period. SG Americas Securities LLC acquired a new stake in Day One Biopharmaceuticals during the second quarter worth $113,000. Point72 DIFC Ltd purchased a new stake in Day One Biopharmaceuticals in the second quarter valued at $124,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Day One Biopharmaceuticals in the 4th quarter valued at $156,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.